SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group (NBIS) is trending after announcing a multi-billion dollar AI infrastructure deal with Microsoft, leading to a significant after-hours surge. The community is buzzing about the implications of the deal being larger than NBIS's market cap and the potential for more contracts with other hyperscalers. Some traders are closely watching related stocks for sympathy plays.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

OCTO is trending due to a significant private placement announcement related to a crypto treasury strategy, sparking a massive short squeeze and a surge in price. The community is actively discussing the potential for continued volatility, the involvement of key figures like Dan Ives, and comparisons to other high-flying stocks with similar catalysts. Concerns about potential dilution and the sustainability of the valuation are also widespread.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as the community buzzes about the demonstration of their solid-state battery technology in a Ducati motorcycle, marking a key milestone. Investors are discussing the potential for increased range and faster charging, viewing this as a move from lab to real-world application. The community speculates on future OEM partnerships and the long-term impact on the EV battery market.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending as investors discuss its potential in the AI infrastructure market, drawing comparisons to peers like $NBIS after its recent deal with Microsoft. The community highlights IREN's AI pivot, NVIDIA partnership, and expanding GPU capacity as key drivers, while some speculate about future hyperscaler deals and revenue potential. Despite some profit-taking, sentiment remains largely positive on the stock's long-term prospects in the growing AI data center space.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors discuss potential deals with major hyperscalers, particularly after NBIS announced a deal with Microsoft, fueling speculation of similar partnerships for APLD. The community is excited about upcoming contracts and potential short squeezes, with discussions around the broader AI infrastructure boom and APLD's position in the data center sector. Recent discussions also mention the launch of a leveraged ETF tracking APLD.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending due to a potential breakout, with investors closely watching Hong Kong market activity for confirmation. Community discussions revolve around the stock's undervaluation and anticipation of a price surge, despite some concerns about profitability and competition in the food delivery sector. The broader context involves optimism around Chinese equities, with some seeing JD.com as a laggard poised to catch up with peers like BABA.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

ASST is trending due to an upcoming merger vote with Strive, anticipated to position the company as a Bitcoin treasury asset manager with substantial funding. The community is discussing the potential for a significant short squeeze, drawing comparisons to other high-flying crypto-related stocks. High short interest and borrow fees are contributing to the heightened speculation around the vote's outcome and its potential impact.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc is trending as the community discusses its potential for a breakout, driven by its attractive valuation and small float. Some are debating the impact of expiring warrants and potential partnerships, while others are focused on contrasting ROOT's fundamentals with competitors in the insurance sector. Bullish sentiment seems to be building for a potential short squeeze.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, in combination with Tirzepatide, helped preserve lean mass during Tirzepatide-induced weight loss in a mid-stage study.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-positive-phase-2-embraze-trial-results">trial</a> demonstrated that 30% of the total weight loss with Tirzepatide alone was due to lean mass loss. Tirzepatide is the active ingredient in Eli Lilly's weight loss therapy Zepbound.Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.Reduction in body weight, however, was marginally higher in patients who received Tirzepatide alone.No subjects experienced serious adverse events or discontinuations considered to be related to apitegromab treatment, and there were no deaths, the company added.Akshay Vaishnaw, President of R&amp;D, Scholar Rock, said that while therapies like Tirzepatide have been an effective innovation for people with obesity, they result in substantial loss of lean muscle mass for patients, leading to unwanted health risks.Vaishnaw added that the company is focused on preparing for the launch of Apitegromab and, following its potential approval for spinal muscular atrophy, looks forward to studying it in a range of neuromuscular diseases with high unmet needs.Approval for Apitegromab in spinal muscular atrophy is expected by late September.Scholar Rock is not alone in attempting to preserve lean mass during drug-induced weight loss. Earlier this month, Regeneron (REGN) said that a mid-stage trial demonstrated that approximately 35% of Semaglutide-induced weight loss was due to loss of lean mass. However, combining Semaglutide, the active ingredient in Novo Nordisk’s weight loss drug Wegovy, with Regeneron’s Trevogrumab with or without Garetosmab helped preserve lean mass while increasing loss of fat mass, the company said.On Stocktwits, retail sentiment around Scholar Rock jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_1_49_41_PM_png_73aabfb93c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, noted that the lack of increased weight loss with the combination compared to Tirzepatide alone is bearish.<stembedurl>https://stocktwits.com/BioLong123/message/618251994</stembedurl><a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> is down by 18% this year but up by over 320% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/coinbase-circle-pop-as-stablecoin-legislation-clears-senate/chlsfGnRR2K">Coinbase, Circle Pop As Stablecoin Legislation Clears Senate – But These Two Stocks Took A Hit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Equity

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.



Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” takeover potential.Jefferies thinks big pharma companies are "still on the hunt" for deals as Pfizer (PFE), Biogen (BIIB), Merck (MRK), Eli Lilly (LLY), Gilead (GILD), and others have publicly discussed active business development to "fill voids."Jefferies named South San Francisco-based Akero among the names it believes hold promise, alongside Scholar Rock (SRRK).The firm noted that Akero has potential sales of $2 billion to $3 billion and "clean and strong" Phase II data of its lead product candidate, Efruxifermin, in patients with non-alcoholic Steatohepatitis.As for Scholar Rock (SRRK), Jefferies deems it a promising target with likely approval for its investigational treatment Apitegromab in spinal muscular atrophy by late September.The company’s upcoming mid-stage trial data of Apitegromab in obesity "could be a clearing event" that could help simplify the stock's valuation, it added.On Stocktwits, retail sentiment around Akero stayed within ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:625/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_36_24_PM_png_6b185bcea0.webp" alt="AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="625" height="66"><figcaption>AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, all 11 analysts covering AKRO rate it a ‘Buy’ or higher. The stock has an average price target of $76.30.Meanwhile, retail sentiment around SRRK stayed ‘bearish’ over the last 24 hours while message volume took a dip from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:633/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_37_19_PM_png_cb246dfd4a.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="633" height="65"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> All of the 10 analysts covering SRRK also rate it ‘Buy’ or higher, with an average price target of $49.67.While <a href="https://stocktwits.com/symbol/AKRO">AKRO</a> has nearly doubled its value this year, <a href="https://stocktwits.com/symbol/SRRK">SRRK</a> is down by over 25%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/merck-gets-fda-approval-for-keytruda-in-more-head-and-neck-cancer-patients/chliQJzRRbZ">Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mergers and Acquisitions message in neon lights. (Image Courtesy: Getty Images)

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased

Jefferies thinks big pharma companies are "still on the hunt" for deals. 

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases...

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious...

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRRK News

SRRK Scholar Rock Holding Corp